Malignant neoplasm of supraglottis
ICD-10 C32.1 is a billable code used to indicate a diagnosis of malignant neoplasm of supraglottis.
Malignant neoplasm of the supraglottis refers to cancer that originates in the supraglottic region of the larynx, which includes structures above the vocal cords, such as the epiglottis and the arytenoids. This type of laryngeal cancer is often associated with risk factors such as tobacco use, excessive alcohol consumption, and human papillomavirus (HPV) infection. Symptoms may include hoarseness, difficulty swallowing, and a persistent cough. Diagnosis typically involves laryngoscopy and biopsy to confirm malignancy. Treatment options may include surgery, radiation therapy, and chemotherapy, with a focus on voice preservation when feasible. Staging of the cancer is crucial for determining the appropriate treatment plan and prognosis, utilizing the TNM classification system, which assesses tumor size (T), lymph node involvement (N), and metastasis (M). Early detection and intervention are key to improving outcomes for patients with this condition.
Detailed descriptions of tumor characteristics, staging, and treatment plans.
Diagnosis and management of laryngeal cancer, including surgical interventions and voice rehabilitation.
Accurate documentation of voice preservation techniques and outcomes is critical for coding.
Comprehensive treatment plans, including chemotherapy and radiation therapy details.
Management of advanced laryngeal cancer and palliative care considerations.
Documentation must reflect the multidisciplinary approach to treatment.
Used for diagnosis of suspected laryngeal cancer.
Document indication for procedure and findings.
Otolaryngologists must ensure thorough documentation of biopsy results.
Common symptoms include hoarseness, difficulty swallowing, throat pain, and a persistent cough. Patients may also experience changes in voice quality.
